Measures that target Russia’s core industries will depress consumption and investment
Tim Kobe, the man behind the Apple Store's signature touches, remembers what Jobs taught him about retail design
In offering conflicting opinions within hours, two federal courts have set up a fight at the Supreme Court over the Affordable Care Act
Xiaomi Chief Executive Officer Lei Jun unveils the Mi4, a metal-backed iPhone-esque smartphone with a 5-inch display, the latest Qualcomm Snapdragon chip, and a $320 price tag
A months-long public-relations debacle is taking a heavy toll on the operators of dark pools
The furniture manufacturer of midcentury classics acquires its largest retail outlet
That an accordion-playing parodist has become one of the most enduring musical acts of our time is, well, a little weird
A new report shows young college-educated professionals will wait a long time to see the financial rewards of their degree.
Profiled companies pay the recruiting service, but job-seekers don't
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.